Outlook and Predictions for Major Mass Tort Litigation in 2025
Outlook and Predictions for Major Mass Tort Litigation in 2025
An analysis of the most significant mass tort litigation trends expected in 2025, including pharmaceuticals, toxic exposure, technology risks, and legal challenges.
Quick Answer: Mass tort litigation in 2025 will be driven by pharmaceutical safety, environmental exposure (especially PFAS), consumer product defects, and data privacy harms. Courts will continue to favor coordinated MDLs, while plaintiffs face higher scrutiny on causation and qualifying exposure.
Introduction
Mass tort litigation remains one of the most influential forces in the U.S. civil justice system, addressing widespread harm caused by defective products, environmental contamination, pharmaceuticals, and emerging technologies.
As 2025 unfolds, mass tort cases are increasingly shaped by advances in science, evolving regulatory standards, and a more refined approach by courts toward consolidation, causation, and settlement structures.
This article examines the most significant mass tort trends expected in 2025, the legal challenges plaintiffs and defendants face, and where large-scale litigation is likely headed next.
What Is Mass Tort Litigation?
A mass tort involves multiple plaintiffs bringing individual claims against one or more defendants for similar harm caused by the same product, substance, or conduct.
Unlike class actions:
- Each plaintiff maintains an individual claim
- Damages are assessed separately
- Cases are often coordinated through Multidistrict Litigation (MDL)
Mass torts allow courts to manage complex litigation efficiently while preserving individualized outcomes.
Key Trends Shaping Mass Tort Litigation in 2025
The pharmaceutical industry has long been a focal point for mass tort litigation, and 2025 is no exception.
Increasing scrutiny on drug safety and medical device effectiveness will likely lead to a surge in cases.
KEY ISSUES:
- mRNA Vaccine Litigation: Claims alleging adverse effects related to mRNA-based vaccines, including those used during the COVID-19 pandemic, may emerge as plaintiffs focus on long-term data.
- Opioid Litigation: While many opioid settlements have been finalized, unresolved cases and secondary litigation (e.g., claims against pharmacies and distributors) may persist.
- Defective Medical Devices: Class III devices like surgical implants and robotic surgical systems will face heightened scrutiny as device failures lead to high-profile injuries.
PREDICTION:
Expect regulatory actions by the FDA and new scientific findings to spark fresh waves of litigation against major pharmaceutical and medical device manufacturers.
If Robert F. Kennedy Jr. is confirmed as the new Trump administration’s Secretary of Health and Human Services, then expect an increased momentum on mRNA vaccine litigation.
Environmental mass tort cases are poised to stall as the new Trump administration is expected to reverse or eliminate policies that address climate change and industrial pollution.
KEY ISSUES:
- PFAS (“Forever Chemicals”) Litigation: Claims involving per- and polyfluoroalkyl substances (PFAS) will likely dominate toxic tort dockets with claims involving aqueous film forming foam (AFFF) contamination becoming the most significant of these cases. Recent studies linking PFAS in AFFF to cancer and other illnesses have intensified lawsuits against chemical manufacturers.
- Water Contamination Cases: Contaminated water supplies, such as those involved in Camp Lejeune cases, will remain a focus as new sites of contamination are uncovered.
- Climate Change Liability: Corporations contributing to greenhouse gas emissions may face lawsuits from municipalities and states seeking to recover damages for climate change-related disasters.
PREDICTION:
Corporate lobbyists will likely gain favor with the Trump administration and delay or diffuse many of the pending or ongoing litigation against chemical manufacturers. However, it is more likely that the scope of injured plaintiffs will be significantly narrowed rather than eliminating litigation altogether.
Litigation against chemical manufacturers may intensify as plaintiffs employ creative legal theories to hold companies accountable for bodily harm towards consumers, particularly military veterans.
Consumer product claims, especially those involving emerging technologies, will see significant growth in certain categories and decline in others where lobbyists hold significant influence in the White House and Capitol Hill.
KEY ISSUES:
- AI-Driven Product Liability: As artificial intelligence (AI) is integrated into consumer products, liability for harm caused by AI errors or bias is expected to generate novel legal disputes.
- E-Cigarette and Vaping Litigation: Claims of health harms caused by vaping products, particularly those targeting youth, will continue to proliferate.
- Electric Vehicle (EV) Defects: The rapid growth of the EV market has revealed safety issues, including battery fires and software malfunctions, which are likely to result in mass tort claims.
PREDICTION:
Mass tort litigation will expand into new areas involving tech-related consumer products, forcing companies to address uncharted legal risks. EVs are likely to see decreased pressure due to Elon Musk’s influence in the White House and plaintiffs are likely to have their cases delayed or dismissed.
Mass tort claims related to workplace environments and conditions are likely to stall as employer rights are prioritized over employee rights.
KEY ISSUES:
- Occupational Exposure to Toxic Substances: Industries involving high exposure to asbestos, silica, and industrial chemicals will face claims from workers alleging long-term health effects.
- COVID-19 Workplace Litigation: Claims related to inadequate protective measures or vaccine mandates may still be in the pipeline as litigation against employers continues.
- Gig Worker Health and Safety: Increased reliance on gig workers may spark litigation over inadequate safety measures or misclassification issues.
PREDICTION:
Employers in industries with significant health and safety risks will face heightened legal exposure in the area of workplace rights; however, the new Trump administration will likely protect employer rights over employee rights in the majority of cases.
Data breaches and misuse of personal information are driving mass tort claims under evolving privacy laws.
KEY ISSUES:
- Biometric Data Litigation: Laws like Illinois’s Biometric Information Privacy Act (BIPA) are setting the stage for mass claims over unauthorized collection or use of biometric data.
- Health Data Breaches: Cyberattacks on healthcare providers and insurers may trigger claims alleging harm from exposure of sensitive personal data.
- AI Privacy Violations: Legal claims related to the misuse of AI for data collection or analysis without consent will likely grow.
PREDICTION:
With increasing regulatory focus on data privacy, companies across industries will face a rising tide of litigation over data security lapses. Big Tech’s influence on the Trump administration may, however, shield many of these corporations from significant liability.
Legal Challenges in Mass Tort Cases
Despite their scale, mass tort claims face significant hurdles:
- Causation and Proof: Plaintiffs must demonstrate a scientifically supported link between exposure and injury, often requiring expert testimony and epidemiological evidence.
- Statutes of Limitation: Delayed diagnosis and long latency periods complicate filing deadlines and discovery rules.
- Qualification Criteria: Courts increasingly require plaintiffs to meet defined exposure, injury, or diagnostic thresholds to remain in coordinated proceedings.
Strategic Considerations for Plaintiffs and Defendants
For Plaintiffs
- Early case screening is critical
- Medical documentation and exposure history matter
- MDL participation can streamline discovery
For Defendants
- Early dispositive motions are increasingly common
- Regulatory compliance defenses are heavily relied upon
- Settlement strategies often emerge after bellwether trials
What to Expect Next in Mass Tort Litigation
Looking ahead, mass tort litigation in 2025 and beyond is expected to feature:
- Narrower plaintiff pools
- Increased reliance on science-based admissibility standards
- Greater emphasis on early resolution for qualified claims
- Continued expansion of environmental and chemical exposure cases
Courts are prioritizing efficiency while maintaining fairness in managing large dockets.
Conclusion
Mass tort litigation remains a powerful legal mechanism for addressing widespread harm in 2025. As science, technology, and regulation continue to evolve, so too will the strategies used by plaintiffs and defendants navigating complex, high-stakes litigation.
Understanding emerging trends allows individuals, attorneys, and institutions to better assess risk, accountability, and potential recovery in large-scale legal disputes.
